About FDA

Office of Pharmaceutical Science (OPS)

Lawrence Yu, Ph.D., Director
Ashley Boam, Deputy Director

Who We Are: 

OPS Organization Chart (PDF - 69KB)

The Office of Pharmaceutical Science (OPS) is an umbrella organization over the activities of chemistry manufacturing and controls (CMC) review in CDER. This includes assessment of product and process design, evaluation of product quality in light of established standards and setting and maintaining new quality standards.

OPS is an integral part of CDER's new and generic drug product application review process. Staff working in these groups have backgrounds in chemistry, biology, biopharmaceutics, clinical pharmacology, immunology, pharmaceutical science, microbiology, pharmacology/toxicology and labeling.

The goal of OPS is to help establish common approaches to the manufacture and formulation of drugs among pharmaceutical manufacturers. OPS contributes to assuring the quality of drug products by providing uniform policies and review processes for the entire pharmaceutical industry through:

OPS engages in scientific research to support decision making for application review, standard setting and for technology development.

Initiatives:

Director's Corner

Presentations on OPS missions and initiatives are compiled.

Events

FDA/PQRI Conference on Evolving Product Quality, September 16-17, 2014

Regulatory Information

How to Contact Us
We ask you to take time to communicate with CDER about this web site.  What information is and isn't useful to you? Are there any additional items or categories of information you would like us to add? Please e-mail Jon Clark, jon.clark@fda.hhs.gov  with feedback about this site.

Page Last Updated: 12/10/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.